Rasagiline + Pramipexole
ApprovedTerminated 2 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Early-stage Parkinson's Disease
Conditions
Early-stage Parkinson's Disease
Trial Timeline
Oct 1, 2008 → Mar 1, 2010
NCT ID
NCT01048229About Rasagiline + Pramipexole
Rasagiline + Pramipexole is a approved stage product being developed by Lundbeck for Early-stage Parkinson's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01048229. Target conditions include Early-stage Parkinson's Disease.
What happened to similar drugs?
0 of 5 similar drugs in Early-stage Parkinson's Disease were approved
Approved (0) Terminated (0) Active (5)
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01048229 | Approved | Terminated |
Competing Products
9 competing products in Early-stage Parkinson's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Anastrozole + Trastuzumab Deruxtecan | Daiichi Sankyo | Phase 2 | 42 |
| ICG | Johnson & Johnson | Pre-clinical | 26 |
| SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab Injection | Jiangsu Hengrui Medicine | Phase 3 | 47 |
| Tamoxifen alone + Tamoxifen + Aminoglutethimide | AstraZeneca | Phase 3 | 40 |
| Cyclophosphamide + Methotrexate + Fluorouracil implant + Goserelin + Tamoxifen | AstraZeneca | Phase 3 | 40 |
| ABP 234 + Pembrolizumab | Amgen | Phase 3 | 47 |
| Rotigotine | UCB | Phase 3 | 40 |
| UCB0599 + Placebo | UCB | Phase 2 | 35 |
| Neratinib + Loperamide + Colesevelam | Puma Biotechnology | Phase 2 | 29 |